Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers
- 1 October 2003
- Vol. 21 (27-30) , 4256-4260
- https://doi.org/10.1016/s0264-410x(03)00454-7
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Education, Culture, Sports, Science and Technology
- Ministry of Health, Labour and Welfare
This publication has 14 references indexed in Scilit:
- Cell Surface-Binding Motifs of L2 That Facilitate Papillomavirus InfectionJournal of Virology, 2003
- IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: Case‐control study of cervical intraepithelial neoplasia in JapanJournal of Medical Virology, 2003
- A Controlled Trial of a Human Papillomavirus Type 16 VaccineNew England Journal of Medicine, 2002
- Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid ProteinJournal of Virology, 2002
- Differential Induction of Mucosal and Systemic Antibody Responses in Women After Nasal, Rectal, or Vaginal Immunization: Influence of the Menstrual CycleThe Journal of Immunology, 2002
- A Phase 1 Study of a Recombinant Viruslike Particle Vaccine against Human Papillomavirus Type 11 in Healthy Adult VolunteersThe Journal of Infectious Diseases, 2001
- Human Papillomavirus Type 16 Minor Capsid Protein L2 N-Terminal Region Containing a Common Neutralization Epitope Binds to the Cell Surface and Enters the CytoplasmJournal of Virology, 2001
- Minor Capsid Protein of Human Genital Papillomaviruses Contains Subdominant, Cross-Neutralizing EpitopesVirology, 2000
- Estimates of the worldwide mortality from 25 cancers in 1990International Journal of Cancer, 1999
- Antibodies to Human Papillomavirus 16, 18, 58, and 6b Major Capsid Proteins among Japanese FemalesJapanese Journal of Cancer Research, 1997